NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH): FDA Approves Protocol Changes for Phase 3 INOpulse Program, Shares Tick Higher
Bellerophon Therapeutics (NASDAQ: BLPH) this morning said the U.S. FDA has approved proposed modifications to the company’s phase 3 program for INOpulse in Pulmonary Arterial Hypertension (PAH). The protocol changes have the potential to reduce the time to market and are expected to result in “substantial” costs savings. “We are gratified that the FDA has agreed with the proposed modifications to our PAH Phase 3 program, which have the potential to make INOpulse available to PAH patients approximately two years earlier than otherwise would have been possible under the original Phase 3 program,” Bellerophon president and CEO Fabian Tenenbaum stated…